Prostate cancer is the most frequent malignant neoplasm in men and the second most common cancer death among American men. Prostate cancer screening is not recommended in men younger than 50 years (unless the patient has a first-degree relative diagnosed with prostate cancer before 65 years of age), in men older than 65 years with a life expectancy of less than 10 years, or in men older than 75 years. Screening for prostate cancer should include testing for prostate specific antigen (PSA). Digital rectal exam (DRE) may also be used as a complementary baseline test.

Refer to ARUP Laboratories’ test offerings below.